Long Non-Coding RNAs in Metastatic Dormancy and Drug-Tolerant Persistence: Regulators of Residual-Cell Plasticity

Cancer can recur when cells that survive dissemination or treatment resume growth. A smaller metastatic burden can reflect slower proliferation, greater immune clearance or fewer viable residual cells. We review long non-coding RNA (lncRNA) perturbation studies that separate these effects. In breast cancer models, NR2F1-AS1 increases NR2F1 translation. This favors dissemination but limits proliferation in the lung. BORG promotes outgrowth from latency through tripartite motif-containing protein 28 (TRIM28), while MALAT1 helps emerging metastases survive immune attack. These experiments illustrate why a change in lesion burden can point to different interventions. The same question arises in drug-tolerant persistence (DTP). Drug-response studies identify candidate RNAs, but few test whether the RNA is needed once reversibly tolerant cells have formed. For relapse prevention, experiments need to count viable residual cells separately from growing lesions and establish when the RNA interaction matters.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-17
DOI
https://doi.org/10.3390/ijms272210321
Primary Topic
Cancer-related molecular mechanisms research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long Non-Coding RNAs in Metastatic Dormancy and Drug-Tolerant Persistence: Regulators of Residual-Cell Plasticity

Li Deng, Xiong Wen Yang, Yu Huang, Yuwen Chen et al.
International Journal of Molecular Sciences
Cancer-related molecular mechanisms research
article

Long Non-Coding RNAs in Metastatic Dormancy and Drug-Tolerant Persistence: Regulators of Residual-Cell Plasticity

Li Deng, Xiong Wen Yang, Yu Huang, Yuwen Chen, Ying Shi, Zhaohui Zhu
article en

Abstract

Cancer can recur when cells that survive dissemination or treatment resume growth. A smaller metastatic burden can reflect slower proliferation, greater immune clearance or fewer viable residual cells. We review long non-coding RNA (lncRNA) perturbation studies that separate these effects. In breast cancer models, NR2F1-AS1 increases NR2F1 translation. This favors dissemination but limits proliferation in the lung. BORG promotes outgrowth from latency through tripartite motif-containing protein 28 (TRIM28), while MALAT1 helps emerging metastases survive immune attack. These experiments illustrate why a change in lesion burden can point to different interventions. The same question arises in drug-tolerant persistence (DTP). Drug-response studies identify candidate RNAs, but few test whether the RNA is needed once reversibly tolerant cells have formed. For relapse prevention, experiments need to count viable residual cells separately from growing lesions and establish when the RNA interaction matters.

International Journal of Molecular SciencesVol. 27(22)
Wuhan Union Hospital (CN), Union Hospital (CN), Huazhong University of Science and Technology (CN)
Good health and well-being
Cancer-related molecular mechanisms research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon